Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03725722 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 251
- Enrollment target
NCT03725722 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 251 participants.
The verdict
NCT03725722, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 251 participants
- Enrollment target
Study Summary
This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe atopic dermatitis (AD).
Interventions
- DRUG Delgocitinib cream
- DRUG Delgocitinib cream vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2018-12-28 |
| Est. Completion | 2020-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03725722
The ClinicalTrials.gov registry entry for NCT03725722 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Delgocitinib cream is the first listed.
NCT03725722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03725722 about?
NCT03725722 is a clinical study titled "Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.". This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe atopic dermatitis (AD).
What is the current status of trial NCT03725722?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 251 participants. The study started on 2018-12-28. Estimated completion is 2020-05-19.
What interventions are being tested in trial NCT03725722?
The interventions under investigation include: Delgocitinib cream (DRUG), Delgocitinib cream vehicle (DRUG).
Who is sponsoring clinical trial NCT03725722?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.